172 related articles for article (PubMed ID: 34815635)
21. Pralatrexate injection combined with CHOP for treatment of PTCL: results from the Fol-CHOP dose-finding phase 1 trial.
Iyer SP; Johnston PB; Barta SK
Blood Adv; 2024 Jan; 8(2):353-364. PubMed ID: 38029357
[TBL] [Abstract][Full Text] [Related]
22. The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study.
Feng X; Guo W; Wang Y; Li J; Zhao Y; Qu L; Yan X; Li J; Guo Q; Young KH; Bai O
Adv Ther; 2022 Jan; 39(1):532-543. PubMed ID: 34797505
[TBL] [Abstract][Full Text] [Related]
23. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
Tilly H; Morschhauser F; Casasnovas O; Molina TJ; Feugier P; Gouill SL; Haioun C; Tournilhac O; Bouabdallah R; Gabarre J; Lamy T; Cabeçadas J; Becker S; Jardin F; Mounier N; Salles G;
Lancet Haematol; 2018 Sep; 5(9):e403-e410. PubMed ID: 30172345
[TBL] [Abstract][Full Text] [Related]
24. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
[TBL] [Abstract][Full Text] [Related]
25. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Huebner D; Kennedy DA; Shustov AR
J Clin Oncol; 2014 Oct; 32(28):3137-43. PubMed ID: 25135998
[TBL] [Abstract][Full Text] [Related]
26. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
27. A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China.
Liu W; Zhao D; Liu T; Niu T; Song Y; Xu W; Jin J; Cai Q; Huang H; Li Z; Hou M; Zhang H; Zhou J; Hu J; Shen J; Shi Y; Yang Y; Zhang L; Zhao W; Ding K; Qiu L; Tan H; Zhang Z; Liu L; Wang J; Xu B; Zhou H; Gao G; Xue H; Bai O; Feng R; Huang X; Yang H; Yan X; Zeng Q; Liu P; Li W; Mao M; Su H; Wang X; Xu J; Zhou D; Zhang H; Ma J; Shen Z; Zhu J
Front Oncol; 2021; 11():750323. PubMed ID: 34804937
[TBL] [Abstract][Full Text] [Related]
28. Dose-escalation of CHOP in non-Hodgkin's lymphoma.
Santoro A; Balzarotti M; Tondini C; Zanini M; Giardini R; Latteri F; Rampinelli I; Bufalino R
Ann Oncol; 1999 May; 10(5):519-25. PubMed ID: 10416000
[TBL] [Abstract][Full Text] [Related]
29. Chidamide Maintenance Therapy Following Induction Therapy in Patients With Peripheral T-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Case Series From China.
Guo W; Wang X; Li J; Yin X; Zhao Y; Tang Y; Wang A; Bai O
Front Oncol; 2022; 12():875469. PubMed ID: 35747802
[TBL] [Abstract][Full Text] [Related]
30. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study.
Foss FM; Sjak-Shie N; Goy A; Jacobsen E; Advani R; Smith MR; Komrokji R; Pendergrass K; Bolejack V
Leuk Lymphoma; 2013 Jul; 54(7):1373-9. PubMed ID: 23278639
[TBL] [Abstract][Full Text] [Related]
31. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
32. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial.
Shimada K; Yamaguchi M; Atsuta Y; Matsue K; Sato K; Kusumoto S; Nagai H; Takizawa J; Fukuhara N; Nagafuji K; Miyazaki K; Ohtsuka E; Okamoto M; Sugita Y; Uchida T; Kayukawa S; Wake A; Ennishi D; Kondo Y; Izumi T; Kin Y; Tsukasaki K; Hashimoto D; Yuge M; Yanagisawa A; Kuwatsuka Y; Shimada S; Masaki Y; Niitsu N; Kiyoi H; Suzuki R; Tokunaga T; Nakamura S; Kinoshita T
Lancet Oncol; 2020 Apr; 21(4):593-602. PubMed ID: 32171071
[TBL] [Abstract][Full Text] [Related]
33. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.
Chiappella A; Tucci A; Castellino A; Pavone V; Baldi I; Carella AM; Orsucci L; Zanni M; Salvi F; Liberati AM; Gaidano G; Bottelli C; Rossini B; Perticone S; De Masi P; Ladetto M; Ciccone G; Palumbo A; Rossi G; Vitolo U;
Haematologica; 2013 Nov; 98(11):1732-8. PubMed ID: 23812930
[TBL] [Abstract][Full Text] [Related]
34. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
[TBL] [Abstract][Full Text] [Related]
35. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S; O'Connor OA; Pro B; Illidge T; Fanale M; Advani R; Bartlett NL; Christensen JH; Morschhauser F; Domingo-Domenech E; Rossi G; Kim WS; Feldman T; Lennard A; Belada D; Illés Á; Tobinai K; Tsukasaki K; Yeh SP; Shustov A; Hüttmann A; Savage KJ; Yuen S; Iyer S; Zinzani PL; Hua Z; Little M; Rao S; Woolery J; Manley T; Trümper L;
Lancet; 2019 Jan; 393(10168):229-240. PubMed ID: 30522922
[TBL] [Abstract][Full Text] [Related]
36. [A phase Ⅰ dose-escalating trial of pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine and prednisone for aggressive non-Hodgkin lymphoma].
Shen WN; Ji DM; Xue K; Zhang QL; Lyu FF; Hong XN; Cao JN; Guo Y
Zhonghua Xue Ye Xue Za Zhi; 2016 Dec; 37(12):1044-1048. PubMed ID: 28088967
[TBL] [Abstract][Full Text] [Related]
37. Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report.
Wang XT; Guo W; Sun M; Han W; Du ZH; Wang XX; Du BB; Bai O
World J Clin Cases; 2020 Jul; 8(14):3122-3129. PubMed ID: 32775395
[TBL] [Abstract][Full Text] [Related]
38. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V
Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434
[TBL] [Abstract][Full Text] [Related]
39. Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review.
Makita S; Maeshima AM; Maruyama D; Izutsu K; Tobinai K
Onco Targets Ther; 2018; 11():2287-2293. PubMed ID: 29719411
[TBL] [Abstract][Full Text] [Related]
40. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.
Rai S; Kim WS; Ando K; Choi I; Izutsu K; Tsukamoto N; Yokoyama M; Tsukasaki K; Kuroda J; Ando J; Hidaka M; Koh Y; Shibayama H; Uchida T; Yang DH; Ishitsuka K; Ishizawa K; Kim JS; Lee HG; Minami H; Eom HS; Kurosawa M; Lee JH; Lee JS; Lee WS; Nagai H; Shindo T; Yoon DH; Yoshida S; Gillings M; Onogi H; Tobinai K
Haematologica; 2023 Mar; 108(3):811-821. PubMed ID: 36200417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
